QUOTE AND NEWS
MarketWatch  Jan 18  Comment 
Shares of CoLucid Pharmaceuticals Inc. soared 31% in premarket trade Wednesday, after the developer treatments for acute migraines agreed to be acquired by Eli Lilly & Co. for $960 million in cash. Under terms of the deal, Eli Lilly will pay...
Benzinga  Jan 17  Comment 
Credit Suisse is bullish on Eli Lilly and Co (NYSE: LLY), saying the recent FDA delay on rheumatoid arthritis drug baricitinib is only a short-term setback for the pharma major. But, the brokerage acknowledges the stock could see some modest...
newratings.com  Jan 17  Comment 
INDIANAPOLIS (dpa-AFX) - The FDA's decision on rheumatoid arthritis drug candidate Baricitinib, being developed by Eli Lilly and Co. (LLY) and Incyte Corp. (INCY), has now been postponed by 3 months to April 19, 2017. Baricitinib, whose...
newratings.com  Jan 13  Comment 
INDIANAPOLIS (dpa-AFX) - Drug maker Eli Lilly and Co. (LLY) said Thursday that it has received a favorable court ruling regarding the vitamin regimen patent for its cancer drug Alimta. The court ruled that a proposed generic equivalent from...
FiercePharma  Jan 12  Comment 
Eli Lilly's Alimta escapes early generics—and a sales hit—with patent win over Teva esagonowsky Thu, 01/12/2017 - 13:02
The Hindu Business Line  Jan 9  Comment 
Ajanta Pharma has received approval for duloxetine hydrochloride delayed release capsules from the US Food and Drug Administration. In an exchange filing, the company said it will launch the drug in...
newratings.com  Jan 9  Comment 
INDIANAPOLIS (dpa-AFX) - Eli Lilly and Co. (LLY) said that it agreed to acquire CoLucid Pharmaceuticals Inc. (CLCD) for $46.50 per share or about $960 million. CoLucid Pharmaceuticals is a public biopharmaceutical company developing an...
MedPage Today  Jan 6  Comment 
(MedPage Today) -- Trial data support ambrisentan plus tadalafil
Financial Times  Jan 5  Comment 
David Ricks believes US drugmaker can ride ‘second wave’ of immunotherapy drugs




Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki